T1	Participants 90 111	rheumatoid arthritis:
T2	Participants 201 226	rheumatoid arthritis (RA)
T3	Participants 473 490	28 joints (DAS28)
T4	Participants 545 659	patients with RA in whom disease had remained active despite treatment with disease-modifying antirheumatic drugs.
